Rhenman & Partners Asset Management AB - Q1 2022 holdings

$1.01 Billion is the total value of Rhenman & Partners Asset Management AB's 89 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .

 Value Shares↓ Weighting
DCPH ExitDECIPHERA PHARMACEUTICALS INC$0-60,000
-100.0%
-0.04%
EPZM ExitEPIZYME INC$0-265,000
-100.0%
-0.05%
INNV ExitINNOVAGE HLDG CORP$0-150,000
-100.0%
-0.05%
FGEN ExitFIBROGEN INC$0-200,000
-100.0%
-0.19%
VCRA ExitVOCERA COMMUNICATIONS INC$0-60,000
-100.0%
-0.26%
SAGE ExitSAGE THERAPEUTICS INC$0-115,000
-100.0%
-0.33%
ZBH ExitZIMMER BIOMET HOLDINGS INC$0-90,000
-100.0%
-0.77%
HCA ExitHCA HEALTHCARE INC$0-59,000
-100.0%
-1.01%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-05-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
UNITEDHEALTH GROUP INC40Q3 20234.0%
BIOMARIN PHARMACEUTICAL INC40Q3 20235.0%
ALKERMES PLC40Q3 20233.3%
LILLY ELI & CO39Q3 20235.8%
CVS HEALTH CORP39Q3 20233.5%
INTRA-CELLULAR THERAPIES INC39Q3 20232.4%
EDWARDS LIFESCIENCES CORP39Q3 20231.7%
VERTEX PHARMACEUTICALS INC38Q3 20234.3%
REVANCE THERAPEUTICS INC38Q3 20230.9%
ABBVIE INC37Q3 20234.4%

View Rhenman & Partners Asset Management AB's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-13
13F-HR/A2023-11-13
13F-HR2023-11-09
13F-HR2023-08-11
13F-HR2023-05-12
13F-HR2023-02-13
13F-HR2022-11-14
13F-HR2022-08-12
13F-HR2022-05-13
13F-HR2022-02-11

View Rhenman & Partners Asset Management AB's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (1013559000.0 != 1013563000.0)

Export Rhenman & Partners Asset Management AB's holdings